Clinical Trial Update: Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the NDV-3A vaccine for preventing Staphylococcus aureus colonization has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Infection

Drugs mentioned

• NDV-3A vaccine (NDV-3A)

Snippet

Sponsor: NovaDigm Therapeutics, Inc. | Conditions: Staphylococcus Aureus | Phase 2 | Status: COMPLETED